Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre‐emptive pharmacogenomic testing

To investigate the longitudinal exposure of English primary care patients to pharmacogenomic drugs to inform design of pre‐emptive testing.

• Publication year

  2019

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2019-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcp.14100PMID 31454087PMCID PMC6955399
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The ubiquitous

  2023cited by this paper
• Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre‐emptive pharmacogenomic testing

  2019cited by this paper
• The ‘top 100’ drugs and classes in England: an updated ‘starter formulary’ for trainee prescribers

  2018cited by this paper
• Spatial distribution of clinical computer systems in primary care in England in 2016 and implications for primary care electronic medical record databases: a cross-sectional population study

  2018influential reference
• An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes

  2018cited by this paper
• The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen.

  2017cited by this paper
• The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

  2017cited by this paper
• Integrating pharmacogenomics into electronic health records with clinical decision support.

  2016cited by this paper
• Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.

  2016cited by this paper
• Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network

  2016cited by this paper
• Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available

  2016cited by this paper
• A conversation with Susan Band Horwitz.

  2015cited by this paper
• Preemptive Clinical Pharmacogenetics Implementation: Current programs in five United States medical centers

  2015cited by this paper
• Data Resource Profile: Clinical Practice Research Datalink (CPRD)

  2015influential reference
• Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.

  2015cited by this paper
• Table of Pharmacogenomic Biomarkers in Drug Labeling

  2015cited by this paper
• Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol.

  2014cited by this paper
• Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing

  2013cited by this paper
• Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics.

  2013cited by this paper
• Pharmacogenomics Knowledge for Personalized Medicine

  2012cited by this paper
• Pharmacogenomics and Individualized Medicine: Translating Science Into Practice

  2012cited by this paper
• Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project

  2012cited by this paper
• Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping

  2012cited by this paper
• Putting prevention first - vascular checks: risk assessment and management

  2010cited by this paper
• HLA-B*5701 screening for hypersensitivity to abacavir.

  2008cited by this paper
• HLA-B*5701 screening for hypersensitivity to Abacavir(A)

  2008cited by this paper
• Elective bridging to recovery after repair: the surgical approach to ventricular reverse remodeling.

  2008cited by this paper

• Use of medications with pharmacogenomic guidelines and adverse outcomes in hospitalised older patients: a retrospective cross-sectional study

  2026cites this paper
• Self‐Reported Pharmacogenetic Medication Use in the Our Future Health Cohort

  2026cites this paper
• Ethically Integrating Genomics in Primary Care: An Invitation to Share Implementation Best Practices.

  2025cites this paper
• Revolutionizing anesthesia: AI-driven protein structure prediction and its clinical impact

  2025cites this paper
• Preventing adverse drug reactions and more: current clinical use of pharmacogenetic testing

  2025cites this paper
• Pharmacogenomic analysis and clinical annotation of 635 patients.

  2025cites this paper
• Pharmacogenetics and adverse drug reports: Insights from a United Kingdom national pharmacovigilance database

  2025influential citation
• A feasibility study on implementing pre-emptive pharmacogenomics testing in outpatient clinics in Singapore (IMPT study)

  2025cites this paper
• A United Kingdom nationally representative survey of public attitudes towards pharmacogenomics

  2025cites this paper
• Real‐World Utilization of Medications With Pharmacogenetic Recommendations in Older Adults: A Scoping Review

  2025cites this paper
• Impact and Enablers of Pharmacogenetic-Informed Treatment Decisions—A Longitudinal Mixed-Methods Study Exploring the Patient Perspective

  2025cites this paper
• Pharmacogenomics and CRISPR-based therapies.

  2025cites this paper
• Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline

  2025cites this paper
• Next-generation sequencing in pharmacogenomics – fit for clinical decision support?

  2024cites this paper
• Estimating the prevalence of potential and actionable drug‐gene interactions in Irish primary care: A cross‐sectional study

  2024cites this paper
• Co-Occurring Methylenetetrahydrofolate Reductase (MTHFR) rs1801133 and rs1801131 Genotypes as Associative Genetic Modifiers of Clinical Severity in Rett Syndrome

  2024cites this paper
• Implementation of Pre-emptive Pharmacogenomics Testing in Outpatient Clinics in Asia (IMPT study)

  2024cites this paper
• CYP2C19 genetic testing for Mavacamten and ischaemic stroke treatment: What does the result mean for cardiovascular prescribers in the UK and Europe?

  2024cites this paper
• Pharmacogenetic Testing to Optimise Antidepressant Treatment in Children and Adolescents: A Narrative Review

  2024cites this paper
• Value of Pharmacogenetic Testing Assessed with Real‐World Drug Utilization and Genotype Data

  2024cites this paper
• Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical Implementation.

  2024cites this paper
• Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review

  2023cites this paper
• Pharmacogenomics: current status and future perspectives

  2023cites this paper
• A retrospective analysis of preemptive pharmacogenomic testing in 22,918 individuals from China

  2023cites this paper
• Pharmacogenomics in practice: a review and implementation guide

  2023cites this paper
• How to assess pharmacogenomic tests for implementation in the NHS in England

  2023cites this paper
• Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study

  2023cites this paper
• Patient-Level Exposure to Actionable Pharmacogenomic Medications in a Nationally Representative Insurance Claims Database

  2023cites this paper
• Pharmacogenetic testing to optimise prescribing – the future standard of care?

  2022cites this paper
• Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database

  2022influential citation
• A Theory-Informed Systematic Review of Barriers and Enablers to Implementing Multi-Drug Pharmacogenomic Testing

  2022cites this paper
• Pharmacogenetics: optimising prescribing in primary care

  2022cites this paper
• Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.

  2022cites this paper
• Pharmacogenomics: Relevance and opportunities for clinical pharmacology

  2022cites this paper
• Estimating the potential impact of implementing pre‐emptive pharmacogenetic testing in primary care across the UK

  2021cites this paper
• Pharmacogenomics spotlight commentary: From the United Kingdom to global populations

  2021influential citation
• Documenting Pharmacogenomic Test Results in Electronic Health Records: Practical Considerations for Primary Care Teams

  2021cites this paper
• Life-time Actionable Pharmacogenetic Drug Use: A Population-based Cohort Study in 86 040 Young People With and Without Mental Disorders in Denmark

  2021cites this paper
• Pharmacogenomic alerts: Developing guidance for use by healthcare professionals

  2021cites this paper
• Pharmacogenomics: A road ahead for precision medicine in psychiatry

  2021cites this paper
• Pharmacogenomic testing to support prescribing in primary care: a structured review of implementation models

  2021cites this paper
• Retrospective Review of Pharmacogenetic Testing at an Academic Children’s Hospital

  2020cites this paper
• Pharmacogenomics for Primary Care: An Overview

  2020cites this paper
• Assessment of primary care practitioners' attitudes and interest in pharmacogenomic testing.

  2020cites this paper
• Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre‐emptive pharmacogenomic testing

  2019cites this paper
• An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes

  2018cites this paper